Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice

Abstract

Today, chronic obstructive pulmonary disease is the fourth global cause of deaths worldwide. A number of studies showed that 11 to 16 million people might suffer from the chronic obstructive pulmonary disease in Russia. The prevalence and high mortality of this disease lead to a significant socio-economic burden. A pharmacoeconomic comparison of two alternative drug technologies in the studied groups grants the reasonable opportunity to transfer patients to the domestic analogues, confirming that efficiency unit costs for using Tiotropium-native and Ipraterol-native are lower than the same costs for using the foreign drugs Spiriva and Berodual.

Keywords

• chronic obstructive pulmonary disease
• pharmacoeconomic analysis
• tiotropium bromide
• fenoterol
• ipratropium bromide
• ipraterol-nativ
• tiotropium-nativ